{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:00Z","timestamp":1787026680400,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2020IT0012"],"award-info":[{"award-number":["2020IT0012"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Considering the risk of reactivation of latent tuberculosis infection (LTBI), not only before starting tumor necrosis factor inhibitors but also before non-TNF inhibitor therapy, LTBI screening is routinely recommended for patients with inflammatory bowel disease (IBD). However, data on the positive conversion of LTBI test results during non-TNF inhibitor therapy are scarce. Among IBD patients treated with vedolizumab and\/or ustekinumab, a total of 91 patients who had negative baseline interferon-gamma release assay (IGRA) results, assessed by QuantiFERON\n                    <jats:sup>\u00ae<\/jats:sup>\n                    -TB Gold In-tube or QuantiFERON\n                    <jats:sup>\u00ae<\/jats:sup>\n                    -TB Gold Plus, were enrolled. Serial LTBI test results after starting non-TNF inhibitor therapy were collected, and patients' clinical characteristics were analyzed. Positive IGRA conversion was observed in six of 91 patients (6.6%). The cumulative IGRA conversion\u2013free survival rates after starting therapy were 97.7% after 1 year and 86.7% after 2 years. Ulcerative colitis was more common among converters compared with non-converters (66.7 vs. 23.5%,\n                    <jats:italic>P<\/jats:italic>\n                    = 0.040). Among six converters, four had been treated with vedolizumab, one with ustekinumab, and the other with vedolizumab followed by ustekinumab. All six patients had been previously exposed to TNF inhibitors before non-TNF inhibitor therapy: five to infliximab and one to both infliximab and adalimumab. After positive IGRA conversion, none of the six converters developed active tuberculosis while maintaining non-TNF inhibitor therapy (median 6.8 months, range 0.4\u201332.1 months). Positive IGRA conversion among IBD patients treated with vedolizumab and\/or ustekinumab appears to occur somewhat frequently, but its clinical implications remain to be elucidated.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2021.670242","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T02:14:30Z","timestamp":1621563270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors"],"prefix":"10.3389","volume":"8","author":[{"given":"Kyuwon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Wook","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Sik","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jae","family":"Myung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-Kyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong Duk","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3346\/jkms.2015.30.2.173","article-title":"The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-alpha blockers","volume":"30","author":"Byun","year":"2015","journal-title":"J Korean Med Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3109\/00365521.2014.1000960","article-title":"Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-\u03b1 inhibitor","volume":"50","author":"Byun","year":"2015","journal-title":"Scand J Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5217\/ir.2018.16.1.4","article-title":"Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment","volume":"16","author":"Park","year":"2018","journal-title":"Intest Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2019","journal-title":"J Crohns Colitis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4046\/trd.2014.76.6.261","article-title":"Diagnosis and treatment of latent tuberculosis infection due to initiation of anti-TNF therapy","volume":"76","author":"Shim","year":"2014","journal-title":"Tuberc Respir Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjy057","article-title":"A prospective study to monitor for tuberculosis during anti-tumour necrosis factor therapy in patients with inflammatory bowel disease and immune-mediated inflammatory diseases","volume":"12","author":"Lee","year":"2018","journal-title":"J Crohns Colitis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00296-019-04510-6","article-title":"Positive conversion of interferon-\u03b3 release assay in patients with rheumatic diseases treated with biologics","volume":"40","author":"Kim","year":"2020","journal-title":"Rheumatol Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","article-title":"Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis","volume":"115","author":"Kedia","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jaad.2019.12.033","article-title":"Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea","volume":"82","author":"Cho","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1513\/AnnalsATS.201405-188OC","article-title":"Reproducibility of interferon gamma (IFN-\u03b3) release assays. A systematic review","volume":"11","author":"Tagmouti","year":"2014","journal-title":"Ann Am Thorac Soc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.tube.2018.06.002","article-title":"Borderline QuantiFERON results and the distinction between specific responses and test variability","volume":"111","author":"Uzorka","year":"2018","journal-title":"Tuberculosis."},{"key":"B19","unstructured":"Korean Guidelines for Tuberculosis2020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1378\/chest.68.3.465","article-title":"False tuberculin test results","volume":"68","author":"Comstock","year":"1975","journal-title":"Chest."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1001\/jama.293.22.2756","article-title":"Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country","volume":"293","author":"Kang","year":"2005","journal-title":"JAMA."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.670242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T02:14:32Z","timestamp":1621563272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.670242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":21,"alternative-id":["10.3389\/fmed.2021.670242"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.670242","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"article-number":"670242"}}